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Macrophagic myofasciitis (MMF) is an emerging condition characterized by specific mus-
cle lesions assessing abnormal long-term persistence of aluminum hydroxide within
macrophages at the site of previous immunization. Affected patients usually are middle-
aged adults, mainly presenting with diffuse arthromyalgias, chronic fatigue, and marked
cognitive deficits, not related to pain, fatigue, or depression. Clinical features usually corre-
spond to that observed in chronic fatigue syndrome/myalgic encephalomyelitis. Represen-
tative features of MMF-associated cognitive dysfunction include dysexecutive syndrome,
visual memory impairment, and left ear extinction at dichotic listening test. Most patients
fulfill criteria for non-amnestic/dysexecutive mild cognitive impairment, even if some cogni-
tive deficits appear unusually severe. Cognitive dysfunction seems stable over time despite
marked fluctuations. Evoked potentials may show abnormalities in keeping with central ner-
vous system involvement, with a neurophysiological pattern suggestive of demyelination.
Brain perfusion SPECT shows a pattern of diffuse cortical and subcortical abnormalities,
with hypoperfusions correlating with cognitive deficiencies. The combination of mus-
culoskeletal pain, chronic fatigue, and cognitive disturbance generates chronic disability
with possible social exclusion. Classical therapeutic approaches are usually unsatisfactory
making patient care difficult.
Keywords: aluminum, vaccines, myofasciitis, myalgias, chronic fatigue syndrome, mild cognitive impairment,
neglected diseases, CCL2
Macrophagic myofasciitis (MMF) is an emerging condition,
first reported in 1998 in adult patients presenting with chronic
fatigue and arthromyalgias and defined by the presence of stereo-
typed inflammatory lesions at muscle biopsy (1). MMF lesion
is very specific and characterized by (i) a focal epi-, peri-, and
endomysial inflammatory infiltrate, mainly formed of large cohe-
sive basophilic macrophages, with PAS-positive cytoplasmic con-
tent; (2) the presence of T-cells; and (3) the absence of signif-
icant myofiber injury (1). Afterwards, it was shown that MMF
lesions correspond to long-lasting aluminic granulomas, result-
ing from previous intramuscular (i.m.) injection of aluminum-
adjuvanted vaccines (2–4). Most recent works delineated the cog-
nitive dysfunction associated with MMF (5, 6) and emphasized the
neurological component of MMF-associated clinical syndrome
(MACS) (4, 7). MMF belongs to rare diseases (Orpha num-
ber #ORPHA592, ICD-10 #M60.8, http://www.orpha.net/) and
its prevalence is not exactly known. From 1993 to 2013, more
than 600 cases were diagnosed in Henri Mondor hospital, and,
to date, 293 patients are registered in our database. The place
of muscle biopsy in the diagnosis approach of chronic myalgias
has been regarded problematic and controversial (8), so explain-
ing the delay elapsed between first symptoms and diagnosis in
MMF patients (Table 1). The retrospective evaluation of 130
consecutive arthro-myalgic patients, previously immunized with
aluminum-containing vaccine, showed that one-third had biopsy-
proven MMF (7). Considering chronic musculoskeletal pain is
very common in primary care practice, MMF appears still under-
diagnosed in France and probably dramatically under-recognized
in other countries where biopsy is not performed in the deltoid
muscle (7).
MEANING OF HISTOLOGICAL MMF LESIONS
ALUMINUM HYDROXIDE IS THE CAUSAL FACTOR OF MMF LESIONS
At the beginning, the origin of MMF was unknown but an envi-
ronmental cause, infectious, or toxic, seemed likely (1). Works
conducted between 1998 and 2001 in Créteil and Bordeaux iden-
tified aluminum hydroxide-adsorbed vaccines as the causal factor
lesions MMF (2). The electron microscopy scanning of biopsy
samples from 40 consecutive patients showed the constant pres-
ence of spiculated inclusions within macrophages corresponding
to aluminum hydroxide crystals. Aluminum hydroxide is a compo-
nent used as immunostimulant adjuvant of many vaccines. MMF
lesions were found only in the deltoid muscles (in adults) and
quadriceps (in children), two conventional vaccinal sites, sup-
porting the hypothesis of a local accumulation of vaccine-derived
aluminum. The evaluation of the first 50 MMF patients estab-
lished that all received at least one i.m. (i.m.) injection of an
aluminic vaccine [hepatitis B virus (HBV): 84%; tetanus toxin
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(TT): 58%; hepatitis A virus (HAV): 19%] before the biopsy
(time 3–96 months, median 36 months). Finally, in experimental
conditions, the i.m. injection of aluminum hydroxide-adsorbed
vaccine in rat induces typical MMF lesions at 21 and 28 days post-
injection. Together, these results established that histopathological
MMF lesions resulted from i.m. injection of aluminum hydroxide-
adjuvanted vaccines (vaccines anti-tetanus, anti-hepatitis A, and
anti-hepatitis B) and demonstrated the unexpected persistence
over several years of this immunostimulant at site of previous
injection (2, 9). Other i.m. injected products containing aluminum
hydroxide may cause MMF, such as allergen preparations used for
desensitization (personal observation).
PATHOLOGICAL SIGNIFICANCE OF MMF LESIONS
Persistence time of aluminum hydroxide after i.m. injection
The i.m. injection of a dose of a vaccine adsorbed on aluminum
hydroxide is sufficient to induce MMF lesions in rats (3), macaque
(10), and mouse (11). The biopersistence of such a lesion is
much longer than originally thought. In rats, these lesions per-
sist 1 year (3) and elimination kinetics depends on the genetic
background. In macaques, 50% of injected animals had detectable
lesions at 1 year. In human beings, the persistence time of post-
vaccinal physiological tissue damage is not known. As long as
we do not have non-invasive and reliable imaging technique to
visualize MMF lesions with certainty, and that can substitute for
biopsy, this data will be impossible to determine, and can only be
based on projections, derived from experimental data obtained in
animals. In 1999, the WHO asked for the mechanisms involved
Table 1 | Epidemiological data from 293 MMF patients registered in
Henri Mondor hospital database.
Age (years) Mean; median 52.7; 53.5
Sex ratio (M/F) 88/205
Mean number of aluminum-containing vaccines
as indicated in vaccination booklets
5; range: 1–12
(data available in
183/293)
Mean persistence time of aluminum (months) 70
Mean delay between onset of symptoms and
biopsy (months)
66.7
Symptoms
Myalgias 254/278 (91%)
Fatigue 248/280 (89%)
Cognitive complaint 107/133 (80%)
Results of neuropsychological testing N =76
Cortico-subcortical profile 64/76 (84.2%)
Isolated callosal deconnexion 4/76 (5.3%)
Isolated dysexecutive syndrome 3/76 (3.9%)
Normal 5/76 (6.6%)
Abnormal evoked potentials 7/22 (31.8%)
Myopathic EMG 15/43 (34.9%)
Elevated CK serum levels 12/48 (25%)
in the persistence of MMF lesion. It proposed that “A plausible
possibility is the existence of a predisposed subset of individuals
with impaired ability to clear aluminum from the deltoid mus-
cle. Whether this reflects a macrophagic dysfunction of either
genetic or acquired origin, or the tail end of a normal distribu-
tion describing the kinetics of aluminum clearance and the local
tissue response to it in the general population, has not yet been
defined” (9). In the current state of knowledge, it can be assumed
that the presence of lesions MMF has no formal pathological
significance if the biopsy was performed within one year after
vaccination (provided that the biopsied muscle is the actual site of
vaccine injection). If the delay is superior to 2 years, the presence
of MMF lesions can be considered pathological. If one considers
that the detection of MMF lesion is purely fortuitous phenom-
enon, the probability to find this lesion would be higher as the
date of biopsy would be close to the date of vaccination. Examina-
tion of the distribution histograms of vaccination-biopsy delays
goes against this hypothesis (Figure 1). The median delay elapsed
between last vaccination and biopsy was found at 53 months (12)
and the distribution profile shows a peak between 4 and 5 years
after vaccination, in complete opposition to the model of “the tail
of the normal distribution” (9). It must be noted that, in the small
subset of patients, the delay was <1 year. In these cases, MMF
lesion can not be considered pathological.
Case of other aluminum-based adjuvants
Aluminum salts other than aluminum hydroxide are used as
vaccine adjuvants. For example, quadrivalent anti-human papil-
loma virus (HPV) vaccine available in France contains alu-
minum hydroxyphosphate. Several observations of girls devel-
oping fatigue/myalgias syndrome after HPV vaccination raised
the question of possible MMF induced by this vaccine. At elec-
tron microscopy, the structure of aluminum hydroxyphosphate
0
5 %
10 %
15 %
0 20 40 60 80 mo
A B
FIGURE 1 | Histogram showing the distribution of patients, according
to the delay elapsed from last injection of aluminum
hydroxide-containing vaccine to muscle biopsy evidencing MMF
lesions. For patients with a delay below 18 months (group A), it is not
possible to consider MMF lesion as certainly pathological. In patients from
group B, the delay is above 18 months indicating an abnormally protracted
persistence time of aluminic granuloma.
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differs from that of aluminum hydroxide (13) suggesting different
physicochemical properties. Macrophages in lesion were fluores-
cent with Morin technique, indicating the presence of aluminum.
Time persistence of granuloma after quadrivalent HPV vaccine
i.m. injection has not yet been determined in mouse to our knowl-
edge. Moreover, further studies are needed to evaluate whether
HPV vaccine may actually induce full-blown MMF in human
beings.
MMF lesion, a post-vaccinal “tattoo”?
The evidence of an abnormally prolonged persistence (several
years) of aluminum hydroxide in muscle tissue after i.m. injec-
tion, has led some authors to speak of “vaccination tattoo” (14,
15), considering MMF lesion as an inert vaccine scar. However,
data from literature contradict this view and it seems somewhat
unwise to regard protracted persistence of aluminum hydroxide
within body as trivial. First, the majority of aluminum-containing
vaccine receivers do not have long-standing MMF at muscle biopsy
(7), considering MMF and non-MMF patients similar for age, sex-
ratio, the number of aluminum-containing vaccines, and the delay
between last vaccine injection and biopsy. Second, histopatholog-
ical investigation indicates that MMF lesion is immunologically
active (2), a finding consistent with the immunostimulant prop-
erties of aluminum hydroxide (16). Third, although it is true that
MMF histological lesions have been observed only at usual sites
of vaccinations so far, experiments performed in rodents (rabbits,
mice) showed that the i.m. injection of aluminum hydroxide is
accompanied by the diffusion of aluminum in the entire body,
including a fraction of the aluminum that penetrates and persists
in brain (11, 17).
MMF-ASSOCIATED CLINICAL SYNDROME
Main clinical manifestations observed in adult patients with per-
sistent MMF lesions at muscle biopsy are the following: (i) chronic
musculoskeletal pain (arthromyalgias); (ii) chronic fatigue; and
(iii) cognitive disorders. These manifestations were described in
a series of studies published between 1998 and 2013 and also in
two reports from French government agencies InVS and ANSM
(formerly AFSSAPS) (18, 19). In contrast to what has been writ-
ten (15), the analysis of these data allows defining quite pre-
cisely the clinical manifestations associated with MMF. MMF is
classified as rare disease #ORPHA 592 in the Orphanet data-
base (http://www.orpha.net/), which is the portal for informa-
tion on rare diseases and orphan drugs, set up by INSERM
(the French National Institute of Health and Medical Research),
the French Directorate General for Health, and the European
Commission. In the International Statistical Classification of Dis-
eases and Related Health Problems (ICD), MMF is referenced
as M608.
CLINICAL MANIFESTATIONS IN PATIENTS WITH MMF
As shown by retrospective analysis of 293 MMMF patients regis-
tered in our database (Table 1), patients are adults (mean age:
52.7 years), mainly women (sex ration M/F: 3/7). Mean delay
between onset of symptoms and biopsy (diagnosis of MMF) was
66.7 months.
Musculoskeletal pain
The analysis of data from the literature (Table 2) and Henri Mon-
dor database (Table 1) allows defining most representative features
of MACS. The development of symptoms is usually slow, over
several months. Diffuse myalgias were observed with a prevalence
ranging from 55 to 96%. Myalgias have been recognized as cardinal
symptoms since first description. The InVS study (18) showed that
myalgias most often began distally in lower limbs, with subsequent
progressive extension to the whole body. At physical examination,
patients usually exhibit only few tender point sites, if not none.
The tenderness at specific tender point sites is a characteristic fea-
ture of fibromyalgia, which are included in the clinical criteria
for fibromyalgia proposed in 1990 by the American College of
Rheumatology (ACR) (20). Logically, most MMF patients did not
meet the 1990 ACR criteria for fibromyalgia (7). In a minority of
patients, myalgias are the only functional complaints. Arthralgias
are less frequently reported (14–84% depending on the series) and
may sometime represent the only complaint. Spinal pain, espe-
cially dorsal, is also frequently observed. Finally, MMF patients
typically present with diffuse arthromyalgias affecting both prox-
imal and distal parts of lower and upper limbs and spine, pain
being usually present at waking up and exacerbated by exer-
cise and daily activity, leading to marked disability. At physical
examination, muscle strength is usually normal, and the presence
of a true deficit must prompt a search for a diffuse muscular
inflammatory/dysimmune process (e.g., inclusions body myosi-
tis or autoimmune necrotizing myopathy) that may associates
with MMF.
Chronic fatigue
Chronic fatigue is the second cardinal symptom, with a prevalence
ranging from 36 to 100% depending on the study (91% in InVS
study). In a study conducted in 30 MMF patients (25), we found
chronic (duration >6 months) fatigue in 28/30 patients (93%).
Fatigue was considered severe and debilitating in 26/30 patients
(87%), caused a significant reduction of activities in 24/30 (80%),
was present more than half the time in 19/30 patients (63%),
affected both physical and mental functioning in 16/30 patients
(53%), and was not alleviated by rest in 13/30 patients (43%). The
majority of patients (16/30, 53%) met the 1991 Oxford or 1994
CDC international criteria for chronic fatigue syndrome (25). In
some patients, chronic fatigue may be the only symptom at onset
and it may precede pain by several months.
MMF-associated cognitive dysfunction
The third cardinal clinical manifestation in MMF is cognitive
impairment (5, 6). This item has been neglected for a long time
and was incorrectly considered as non-specific. Indeed, chronic
pain, chronic fatigue states, and depressive syndromes are known
to impair intellectual or cognitive performance, especially atten-
tion and concentration. In most studies, cognitive disturbances
were not mentioned. The prevalence of cognitive complaints
ranged from 20 to 68% (5, 12, 23–25). In a first comprehensive
study (5), we demonstrated that all MMF patients had quantifi-
able neuropsychological involvement. MMF-associated cognitive
dysfunction (MACD) is usually severe, and did not correlate to
pain, fatigue, depression, disease duration, or drug intake (5, 6).
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Table 2 | Prevalence of main clinical manifestations in MMF patients in published series.
Reference No. of
patients
Myalgias (%) Arthralgias (%) Cognitive
disturbances (%)
Psychiatric
manifestations
Other
(1) 14 86 64 – – Weakness 43%
Fever 28%
Dyspnea 21%
(21) 12 92 58 – – Weakness 42%
Fever 17%
Spinal pain 17%
(22) 7 86 14 14 14 Multiple sclerosis (MS) 100%
(2) 50 94 – – – Autoimmune diseases 34% (MS 12%)
(23, 24) 10 60 30 20 –
(25) 30 87 57 50 50 Chronic fatigue syndrome 53%
(12) 30 88 57 50 53 Autoimmune diseases 19%
(26) 9 55 – – – Neurological signs 44%
(5) 25 96 84 68 (Patients statement) 52 Cognitive dysfunction 100%
(27) 16 56 12.5 – – Chronic fatigue syndrome 50%
(18) 53 81 57 – – Headache 28%
Dyspnea 27%
(19) 28 81 50 – –
Compared to control patients with arthritis and chronic pain,
MMF patients had pronounced and specific cognitive impair-
ment. The cognitive profile combines a dysexecutive syndrome,
memory impairment, and signs of inter-hemispherical discon-
nection (5). Cognitive deficits did not correlate with pain, fatigue,
depression, or disease duration. Most patients fulfilled criteria
for non-amnestic/dysexecutive mild cognitive impairment (MCI)
(Figure 2), even if some cognitive deficits seem unusually severe
(6). MACD is probably the most disabling feature of MMF
but seems stable with time, despite marked fluctuations (6).
Long-term follow-up is needed to determine the evolution of
patients.
Other manifestations
Psychiatric manifestations are unusually frequent in MMF
patients, often leading physicians to consider physical complaints
as psychosomatic. When checked on, the prevalence of mood dis-
orders ranged from 50 to 60% (6, 25). MMF-associated psychiatric
manifestations have not been specifically investigated, to date, but
plausibly they could be consubstantial with the disease and con-
tribute to alter the relations of patients with physicians. Various
other complaints are reported by MMF patients, most regularly
encountered being dyspnea and headache (12).
NATURE OF THE ASSOCIATION BETWEEN HISTOLOGICAL MMF
LESIONS AND SYMPTOMS
The genuineness of the association between general clinical man-
ifestations and focal MMF histopathological lesion has been
repeatedly disputed. However, since its first description, there are
Non-amnesc
5/30
Non-amnesc
mulple domains
12/30
Amnesc
mulple domains
10/30
Non-MCI
3/30
FIGURE 2 | Mild cognitive impairment (MCI) in MMF. Classification of 30
MMF patients according to the neuropsychological profile of cognitive
dysfunction. 27/30 (90%) fulfilled criteria for MCI, of amnestic type/multiple
domains in 10/30 (33%) and of non-amnestic type in 17/30 (56.7%),
multiple domains in 12/30 (40%). Results from Passeri et al. (6).
accumulating evidences in favor of a non-fortuitous association
between the histological lesion and the symptoms presented by
patients. First, in MMF patients, myalgias appear almost always
subsequent to the administration of an aluminum hydroxide-
containing vaccine (2). Second, the retrospective evaluation of
1292 consecutive patients who underwent deltoid muscle biopsy
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for diagnostic purposes showed a highly significant association
(p< 0.0001) between chronic myalgias and the presence of MMF
at biopsy (2). Interestingly, these findings go along the same
lines of a previous large-scale survey identifying myalgias and
arthralgias as adverse effects of anti-HBV vaccination (28). Third,
a case–control study conducted on behalf of AFSSAPS (French
equivalent of FDA) showed that (i) individuals with histological
MMF lesions more frequently reported asthenia at onset than non-
MMF individuals; and (ii) functional limitations due to fatigue
were more important in MMF than in non-MMF individuals
(19). Although only recently delineated, MACD is now recog-
nized as a central feature in MMF, this dysfunction being much
more frequent and severe than suspected by routine neurological
evaluation (5). Importantly, it has been shown that non-specific
factors such as pain, fatigue, depression, or drugs cannot explain
by themselves the entire cognitive impairment and, compared to
painful diseased controls, MMF patients displayed more severe
cognitive deficits. The profile of neuropsychological dysfunction
is comparable to that described in inflammatory or toxic condi-
tions such as multiple sclerosis, human immunodeficiency virus
(HIV) or hepatitis C virus (HCV) infections, or chronic aluminum
exposure, supporting the view that MACD reflects an underlying
organic, inflammatory, or toxic, brain involvement (5).
LABORATORY INVESTIGATIONS IN MMF PATIENTS
Positive diagnosis required to detect persistent MMF lesions at
the surgical biopsy of deltoid muscle in adults and quadriceps
muscle in children (see supra). Increased plasma creatine kinase
(CK) levels may be observed in almost one third of patients.
Unexceptionally, CK levels are increased at onset then get back to
normal. Some patients have sustained increased CK levels; usually
related to ongoing myonecrosis process with complement activa-
tion, usually ascribed to autoimmune mechanism. More generally,
the presence of persisting elevated levels of CK should prompt
the search of another cause of muscle involvement, especially
inflammatory/dysimmune myopathy that may be associated with
MMF (see infra). Baseline aluminum serum levels remain within
reference values (2). However, through measurement of urinary
aluminum excretion, it has been possible to demonstrate alu-
minum overload in one patient with vaccine-associated chronic
fatigue syndrome and MMF (29). Electrodiagnostic testing may
disclose myopathic feature in almost one-third of the patients.
Skeletal muscle MRI is usually uninformative, except in case of
associated diffuse myopathy.
In MMF patients, Gallium-67 (Ga67) scintigraphy disclosed a
characteristic pattern of hyperfixations, mainly observed in fas-
cias and periarticular areas in lower limbs, with a topography
paralleling that of pain (21). These features are different from
those observed in sarcoidosis (nodular lesions) and fibromyal-
gia (normal appearance). Gallium-67 (Ga67) is a radioisotope,
which binds to the transferrin receptor (CD 71), which is espe-
cially expressed on the surface of macrophages and of different
types of activated lymphocytes. However, the histopathological
substratum of scintigraphic abnormalities in MMF has not been
determined so far.
Because of cognitive disorders, most patients underwent rou-
tine brain MRI. Except in the subset of patients in whom MMF
is associated with multiple sclerosis (9.3%) (12, 22), brain MRI
appears poorly informative. Indeed, in a recent study, MRI
was found normal/subnormal in 48% or showed non-specific
brain supratentorial white matter T2-weighted hyperintensities
in 38.5% (6). Other abnormalities included cortical (20%) or
callosal (12%) atrophy. In contrast, functional imaging (single
photon emission tomography, SPECT) was abnormal in 89%,
hypoperfusions mainly affecting hippocampus, amygdala, and
caudatus nucleus (6). When performed, evoked potentials (audi-
tory, visual, and sensory) displayed abnormalities suggestive of
central nervous system (CNS) demyelination in 38.5% MMF
patients (6).
IMMUNOLOGICAL ABNORMALITIES IN MMF
Aluminum hydroxide is a potent activator of the immune sys-
tem. In addition to their general symptoms, 19% of patients have
an autoimmune disease characterized at time of MMF diagno-
sis, including multiple sclerosis, and also autoimmune thyroiditis,
inclusion body myositis, dermatomyositis, rheumatoid arthritis,
and Sjogren’s syndrome (12, 22, 30–32). Protracted immuno-
logical activation may be at the origin of arthralgias and the
chronic fatigue syndrome (33) and the latter could be the result
of augmented adjuvant effect of aluminum hydroxide-containing
vaccines (34). These effects may be associated with a permanent
production of proinflammatory cytokines [interleukin (IL)-1, IL-
6, TNF-α, and GM-CSF], even if reported changes are exces-
sively variable to be used for diagnostic purposes in the syn-
drome chronic fatigue (35–38). The MMF patients frequently
have immunological abnormalities, in particular, an increase in the
number of circulating B lymphocytes, and the presence of autoan-
tibodies usually anti-nuclear and anti-phospholipid (unpublished
data). Extensive cytokine screening showed increase of serum lev-
els of the monocyte chemoattractant protein 1 (CCL2/MCP-1)
in MMF patients compared to healthy subjects. MMF patients
showed no elevation of other cytokines. This contrasted with
inflammatory patients in whom CCL2/MCP-1 serum levels were
unchanged, whereas several other inflammatory cytokines were
elevated (39).
INDIVIDUAL SUSCEPTIBILITY FACTORS
The existence of individual predisposing factors, not yet identi-
fied, to develop a long-lasting post-vaccination MMF associated
with systemic symptoms is suggested by the small proportion
of cases detected among vaccines (9). A genetic predisposition
has been long suspected in patients, particularly on the basis of
familial cases (23, 24, 40, 41). This view is supported by experi-
mental results showing that genetic background is a key factor for
the persistence of post-vaccinal granuloma (3). MMF is charac-
terized by the increase of circulating CCL2/MCP-1, a cytokine
implicated in the penetration of nanomaterials in brain (11,
39). The genotyping of 252 MMF patients and 516 controls in
the CCL2 gene was in favor of the association between haplo-
type rs1024611/rs3760396 and the disease (Odds Ratio: 1,280,
p= 0,088) (11). However, in 94 patients with the correspond-
ing haplotype, the sequencing of 3 exons, 2 introns, and 3.5 kb
upstream sequences in CCL2/MCP1 gene did not reveal anom-
alies. It seems plausible that CCL2 over expression results from a
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Table 3 | Criteria for ASIA [from Shoenfeld and Agmon-Levin (42)].
Major criteria
Exposure to an external stimuli (Infection, vaccine, silicone, adjuvant)
prior to clinical manifestations
The appearance of “typical” clinical manifestations
Myalgia, myositis, or muscle weakness
Arthralgia and/or arthritis
Chronic fatigue, un-refreshing sleep, or sleep disturbances
Neurological manifestations (especially associated with demyelination)
Cognitive impairment, memory loss
Pyrexia, dry mouth
Removal of inciting agent induces improvement
Typical biopsy of involved organs
Minor criteria
The appearance of autoantibodies or antibodies directed at the
suspected adjuvant
Other clinical manifestations (i.e., irritable bowel syn.)
Specific HLA (i.e., HLA DRB1, HLA DQB1)
Evolvement of an autoimmune disease (i.e., MS, SSc)
trans mechanism and pan-genomic approaches (G-WAS, exome)
will be necessary to indentify the genetic variants associated
with MMF.
AUTOIMMUNE/INFLAMMATORY SYNDROME ASSOCIATED
WITH ADJUVANTS
In 2010, Shoenfeld and Agmon-Levin proposed the concept of
autoimmune/inflammatory syndrome induced adjuvants (ASIA)
that includes different clinical syndromes induced by expo-
sure to xenobiotic having immune adjuvant properties (42).
ASIA includes siliconosis (complications associated with silicone-
containing implants), Gulf War syndrome, MMF, and post-
vaccination phenomena. ASIA is characterized by a corpus of
common symptoms including (i) muscle symptoms (myalgias,
muscle weakness); (ii) joint involvement (arthralgia, arthritis);
(iii) chronic fatigue and sleep disorders; and (iv) a neurological
and/or cognitive involvement (Table 3).
CONCLUSION
For decades, vaccines demonstrated their invaluable benefits in
the fight against transmissible diseases. The repeated emergence
of infectious threats crucially points out the need to have vaccines
fully suitable for the widest possible population. The exact biolog-
ical mechanisms leading to the outbreak of clinical manifestations
in patients with long-term persisting MMF lesions are unknown
so far. In the light of the story of MMF, one may consider that it
is timely for health governmental agencies to rethink the methods
for evaluating long-term safety of inorganic compounds and to
support appropriate research programs.
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